ATE443141T1 - Aktivitätsabhänginger neurotropischer faktor iii(adnf iii) - Google Patents

Aktivitätsabhänginger neurotropischer faktor iii(adnf iii)

Info

Publication number
ATE443141T1
ATE443141T1 AT98907407T AT98907407T ATE443141T1 AT E443141 T1 ATE443141 T1 AT E443141T1 AT 98907407 T AT98907407 T AT 98907407T AT 98907407 T AT98907407 T AT 98907407T AT E443141 T1 ATE443141 T1 AT E443141T1
Authority
AT
Austria
Prior art keywords
iii
adnf iii
adnf
activity dependent
iii polypeptides
Prior art date
Application number
AT98907407T
Other languages
English (en)
Inventor
Illana Gozes
Douglas Brenneman
Merav Bassan
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Priority claimed from PCT/US1998/002485 external-priority patent/WO1998035042A1/en
Application granted granted Critical
Publication of ATE443141T1 publication Critical patent/ATE443141T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Lock And Its Accessories (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
AT98907407T 1997-02-07 1998-02-06 Aktivitätsabhänginger neurotropischer faktor iii(adnf iii) ATE443141T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3740497P 1997-02-07 1997-02-07
PCT/US1998/002485 WO1998035042A1 (en) 1997-02-07 1998-02-06 Activity dependent neurotrophic factor iii (adnf iii)

Publications (1)

Publication Number Publication Date
ATE443141T1 true ATE443141T1 (de) 2009-10-15

Family

ID=21894162

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98907407T ATE443141T1 (de) 1997-02-07 1998-02-06 Aktivitätsabhänginger neurotropischer faktor iii(adnf iii)

Country Status (9)

Country Link
EP (2) EP0966533B1 (de)
JP (1) JP4649602B2 (de)
AT (1) ATE443141T1 (de)
AU (1) AU737406B2 (de)
CA (1) CA2279231C (de)
DE (1) DE69841160D1 (de)
DK (1) DK0966533T3 (de)
ES (1) ES2331595T3 (de)
PT (1) PT966533E (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075900A1 (en) * 2004-04-08 2009-03-19 Sadakazu Therapeutic agent for motor neuron disease
WO2006099739A1 (en) * 2005-03-23 2006-09-28 Ramot At Tel-Aviv University Ltd. Use of adnf polypeptides for treating peripheral neurotoxicity
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング,インコーポレイテッド Tim-3とそのリガンドとの相互作用の遮断によるがん治療
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング,インコーポレイテッド ガレクチン-3を遮断することにより炎症性疾患を処置する方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3740497A (en) 1971-06-29 1973-06-19 G Daniell Artificial line bridge subscriber dial long line equipment tester
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4254082A (en) 1978-06-12 1981-03-03 Miles Laboratories, Inc. Specific binding-adsorbent assay test means
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
JPS58215453A (ja) 1982-06-09 1983-12-14 Toray Silicone Co Ltd 室温硬化後塗装可能なオルガノポリシロキサン組成物
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
IL94872A (en) 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
US5075431A (en) 1989-07-26 1991-12-24 City Of Hope Chimeric anti-CEA antibody
US5081235A (en) 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
US6174862B1 (en) * 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
AU667045B2 (en) * 1991-04-22 1996-03-07 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Activity-dependent neurotrophic factor
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US5506132A (en) 1993-07-28 1996-04-09 Sandoz Pharmaceuticals Corporation Human antibodies against varicella-zoster virus
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol

Also Published As

Publication number Publication date
EP2172478A2 (de) 2010-04-07
WO1998035042A2 (en) 1998-08-13
DE69841160D1 (de) 2009-10-29
CA2279231A1 (en) 1998-08-13
AU6322298A (en) 1998-08-26
WO1998035042A8 (en) 2006-11-09
DK0966533T3 (da) 2010-01-04
AU737406B2 (en) 2001-08-16
PT966533E (pt) 2010-01-26
JP2001522228A (ja) 2001-11-13
ES2331595T3 (es) 2010-01-08
JP4649602B2 (ja) 2011-03-16
CA2279231C (en) 2013-11-26
EP0966533B1 (de) 2009-09-16
EP0966533A1 (de) 1999-12-29
EP2172478A3 (de) 2010-07-28

Similar Documents

Publication Publication Date Title
WO2000027875A3 (en) Activity dependent neurotrophic factor iii (adnf iii)
EP1439230A3 (de) Menschliche transmembranprotein TMP-2 gen
EP0477971A3 (en) Human cnp gene and precursor protein
WO1995021919A3 (en) Protein having tpo activity
EP0994728A4 (de) Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
CA2253238A1 (en) Novel agouti-related gene
WO2001079442A3 (en) Albumin fusion proteins
WO2001038486A3 (en) Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies
EP0258411A4 (de) Dns, kodierend für streptavidin, daraus erzeugtes streptavidin, fusierte polypeptide mit aminosäurensequenzen aus streptavidin und verwendungen.
DE60142239D1 (de) DEN PHOSPHORSÄURE-METABOLISMUS, DEN KALZIUM-METABOLISMUS, VERKALKUNG UND DEN VITAMIN D-METABOLISMUS KONTROLLIERENDE POLYPEPTIDE SOWIE FüR DIESE KODIERENDE DNA-MOLEKÜLE
WO2000015659A3 (en) Stomach polypeptide zsig28
ATE443141T1 (de) Aktivitätsabhänginger neurotropischer faktor iii(adnf iii)
WO2000003004A3 (en) Presenilin 2 specific ribozyme
WO1993017031A3 (en) Nucleic acids encoding dystrophin-associated proteins
WO2001062891A3 (en) 207 human secreted proteins
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
WO2000044898A3 (en) Novel agouti and agouti-related peptide analogs
WO2000037613A3 (en) Human akt-3
WO2001000662A3 (en) The use of human fgh-8 polypeptides as neurotrophic agents
WO2003000717A3 (de) Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen
WO2003000889A3 (de) Identifizierung von ses-1 aus c. elegans sowie dessen verwendung
WO2001042292A3 (en) Secreted polypeptide zsig87
WO2002026931A3 (en) 71 human secreted proteins
WO2001057080A3 (en) Neuropeptide-like polypeptide zpep17
WO2001075020A3 (fr) Nouveau polypeptide, neuroproteine humaine y 11, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0966533

Country of ref document: EP

EEFA Change of the company name